{"protocolSection":{"identificationModule":{"nctId":"NCT05634811","orgStudyIdInfo":{"id":"C4601012"},"secondaryIdInfos":[{"id":"NCT05634811","type":"REGISTRY","domain":"ClinicalTrials.gov"},{"id":"2025-000441-15","type":"EUDRACT_NUMBER"},{"id":"2025","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2025"}],"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children","officialTitle":"A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY OF A 6-VALENT OspA-BASED LYME DISEASE VACCINE (VLA15) IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE"},"statusModule":{"statusVerifiedDate":"2026-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-12-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-07-21","type":"ACTUAL"},"completionDateStruct":{"date":"2025-07-21","type":"ACTUAL"},"studyFirstSubmitDate":"2022-11-22","studyFirstSubmitQcDate":"2022-11-22","studyFirstPostDateStruct":{"date":"2022-12-02","type":"ACTUAL"},"resultsFirstSubmitDate":"2026-04-14","resultsFirstSubmitQcDate":"2026-04-14","resultsFirstPostDateStruct":{"date":"2026-05-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-04-14","lastUpdatePostDateStruct":{"date":"2026-05-07","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study is to understand if the study vaccine (called VLA15) is safe in healthy children.\n\nWe are looking for children who:\n\n* are healthy\n* are age 5 through 17\n* have not been diagnosed with any form of Lyme disease in the past\n* have not received any vaccines for Lyme disease in the past\n\nLyme disease happens most often in children of this age. The study vaccine may be used potentially to help prevent Lyme disease. The goal of this study is to get more information about the safety of the study vaccine in this age group.\n\nParticipants will be in this study for about 2 years. During that time, they will receive VLA15 or placebo (sterile saltwater solution) by a \"shot\" in the arm. We will compare experience of children receiving VLA15 to those receiving the placebo. Participants will not know whether they get VLA15 or placebo.\n\nEveryone participating in this study will:\n\n* get the shots in a clinic or in a hospital office\n* receive a total of 4 shots\n* receive the first 3 shots within 6 months\n* receive the last shot about 1 year afterwards\n* need to come to the trial site for 6 planned visits; 4 of these are vaccination visits and 2 are follow-up visits. We will contact you by phone 1 time every year during the study to monitor your experience. You may have extra visits if you experience a severe reaction after a vaccine dose."},"conditionsModule":{"conditions":["Lyme Disease"],"keywords":["Borreliosis","Borrelia burgdorferi","Spirochetes","Vector-Borne Disease","Lyme Disease Vaccine","VLA15","Outer Surface Protein A (OspA)","Ticks"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"OTHER","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":3547,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"VLA15","type":"EXPERIMENTAL","description":"Participants will receive 6-valent OspA-based Lyme disease vaccine (VLA15).","interventionNames":["Biological: VLA15"]},{"label":"Normal Saline (Placebo)","type":"PLACEBO_COMPARATOR","description":"Participants will receive 0.9% sodium chloride solution for injection","interventionNames":["Other: Normal Saline"]}],"interventions":[{"type":"BIOLOGICAL","name":"VLA15","description":"6-valent OspA-based Lyme disease vaccine","armGroupLabels":["VLA15"],"otherNames":["PF-07307405"]},{"type":"OTHER","name":"Normal Saline","description":"0.9% sodium chloride solution for injection","armGroupLabels":["Normal Saline (Placebo)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 1","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in the electronic dairy (e-diary) or by investigators in case report form (CRF) after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on Center for Biologics Evaluation and Research (CBER) toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.","timeFrame":"From Day 1 through Day 7 after Study Vaccination 1 (Vaccination on Day 1, Month 0)"},{"measure":"Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 2","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.","timeFrame":"From Day 1 through Day 7 after Study Vaccination 2 (Vaccination on Day 1, Month 2)"},{"measure":"Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 3","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.","timeFrame":"From Day 1 through Day 7 after Study Vaccination 3 (Vaccination on Day 1, Month 6)"},{"measure":"Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.","timeFrame":"From Day 1 through Day 7 after Study Vaccination 4 (Vaccination on Day 1, Month 18)"},{"measure":"Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days After Any Study Vaccination","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.","timeFrame":"From Day 1 through Day 7 after any study vaccination"},{"measure":"Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 1","description":"Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.","timeFrame":"From Day 1 through Day 7 after Study Vaccination 1 (Vaccination on Day 1, Month 0)"},{"measure":"Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 2","description":"Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.","timeFrame":"From Day 1 through Day 7 after Study Vaccination 2 (Vaccination on Day 1, Month 2)"},{"measure":"Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 3","description":"Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.","timeFrame":"From Day 1 through Day 7 after Study Vaccination 3 (Vaccination on Day 1, Month 6)"},{"measure":"Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)","description":"Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.","timeFrame":"From Day 1 through Day 7 after Study Vaccination 4 (Vaccination on Day 1, Month 18)"},{"measure":"Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days After Any Study Vaccination","description":"Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.","timeFrame":"From Day 1 through Day 7 after any study vaccination"},{"measure":"Percentage of Participants With AEs Through 1 Month Following Study Vaccination 1","description":"An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 1 were included in this outcome measure. AEs included both serious AEs (SAEs) and non-SAEs.","timeFrame":"From Day 1 through 1 Month after Study Vaccination 1 (Vaccination on Day 1, Month 0)"},{"measure":"Percentage of Participants With AEs Through 1 Month Following Study Vaccination 2","description":"An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 2 were included in this outcome measure. AEs included both SAEs and non-SAEs.","timeFrame":"From Day 1 through 1 Month after Study Vaccination 2 (Vaccination on Day 1, Month 2)"},{"measure":"Percentage of Participants With AEs Through 1 Month Following Study Vaccination 3","description":"An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 3 were included in this outcome measure. AEs included both SAEs and non-SAEs.","timeFrame":"From Day 1 through 1 Month after Study Vaccination 3 (Vaccination on Day 1, Month 6)"},{"measure":"Percentage of Participants With AEs Through 1 Month Following Study Vaccination 4 (Booster Dose)","description":"An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 4 were included in this outcome measure. AEs included both SAEs and non-SAEs.","timeFrame":"From Day 1 through 1 Month after Study Vaccination 4 (Vaccination on Day 1, Month 18)"},{"measure":"Percentage of Participants With AEs Through 1 Month Following Any Study Vaccination","description":"An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after any dose were included in this outcome measure.","timeFrame":"From Day 1 through 1 Month after any study vaccination"},{"measure":"Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMCs) Throughout the Study","description":"An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. NDCMCs included conditions that were undiagnosed prior to study entry (diagnosed while in the study and confirmed not to be a preexisting condition) and that were not considered temporary conditions based upon the expected natural history of the condition. An NDCMC was not reported on AE CRF.","timeFrame":"Throughout the study (from study vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months)"},{"measure":"Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study","description":"An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other important medical event.","timeFrame":"Throughout the study (from study vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy participants at enrollment who are determined to be eligible for inclusion in the study. Participants with preexisting chronic medical conditions determined to be stable may be included.\n* Participants and/or participants' parent(s)/guardian who are willing and able to comply with all scheduled visits, study procedures and lifestyle considerations for the duration of the study.\n\nExclusion Criteria:\n\n* Female participants that are pregnant, breastfeeding, or have a positive urine pregnancy test at Visit 1. Sexually active females and fertile males unwilling to use contraception as per protocol.\n* Any contraindication to vaccination or vaccine components, including previous anaphylactic reaction to any vaccine or vaccine-related components.\n* Any diagnosis of Lyme disease within the past 3 months.\n* Any history of Lyme arthritis, carditis, neuroborreliosis, or other disseminated Lyme Disease (LD), regardless of when diagnosed.\n* Known tick bite within the past 4 weeks.\n* Congenital or acquired immunodeficiency or other conditions or treatments associated with immunosuppression that would inhibit the ability to mount an immune response to a vaccine.\n* Other medical, psychiatric condition, active suicidal ideation/behavior or lab abnormality which increases risk of study participation or, in investigator's judgment is inappropriate for the study.\n* Receipt of a previous vaccination for LD.\n* Treatment for LD in the 3 months prior to study intervention administration.\n* Receipt of blood/plasma products or immunoglobulins within 6 months before study intervention administration through conclusion of the study.\n* Receipt of systemic corticosteroids for ≥14 days within 28 days before study intervention administration. Inhaled/nebulized, intra-articular, intrabursal, or topical corticosteroids are permitted.\n* Receipt of chronic systemic treatment with other known immunosuppressant medications, or radiotherapy, within 6 months before study intervention administration.\n* Current use of any prohibited concomitant medication(s) or participants unwilling/unable to use a permitted concomitant medication(s).\n* Participation in other studies involving investigational drugs/vaccines/devices within 28 days prior to study entry and/or during study participation (observational studies are acceptable).\n* Investigator site staff, sponsor/sponsor delegates directly involved in the conduct of the study and their family members; site staff supervised by the investigator and their family members.","healthyVolunteers":true,"sex":"ALL","minimumAge":"5 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"UAB Child Health Research Unit (CHRU)","city":"Birmingham","state":"Alabama","zip":"35233","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"University of Alabama at Birmingham - School of Medicine","city":"Birmingham","state":"Alabama","zip":"35233","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Lakeview Clinical Research","city":"Guntersville","state":"Alabama","zip":"35976","country":"United States","geoPoint":{"lat":34.35823,"lon":-86.29446}},{"facility":"Coast Clinical Research, LLC","city":"Bellflower","state":"California","zip":"90706","country":"United States","geoPoint":{"lat":33.88168,"lon":-118.11701}},{"facility":"Apex Research Group LLC","city":"Fair Oaks","state":"California","zip":"95628","country":"United States","geoPoint":{"lat":38.64463,"lon":-121.27217}},{"facility":"New England Research Associates","city":"Bridgeport","state":"Connecticut","zip":"06606","country":"United States","geoPoint":{"lat":41.17923,"lon":-73.18945}},{"facility":"Stamford Therapeutics Consortium","city":"Stamford","state":"Connecticut","zip":"06905","country":"United States","geoPoint":{"lat":41.05343,"lon":-73.53873}},{"facility":"Children's National Medical Center","city":"Washington D.C.","state":"District of Columbia","zip":"20010","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Bio-Medical Research LLC","city":"Miami","state":"Florida","zip":"33144","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"GCP Research, Global Clinical professionals","city":"St. Petersburg","state":"Florida","zip":"33705","country":"United States","geoPoint":{"lat":27.77086,"lon":-82.67927}},{"facility":"MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research","city":"Tampa","state":"Florida","zip":"33609","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"ForCare Clinical Research","city":"Tampa","state":"Florida","zip":"33613","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Tekton Research, LLC.","city":"Chamblee","state":"Georgia","zip":"30341","country":"United States","geoPoint":{"lat":33.89205,"lon":-84.29881}},{"facility":"ASR, LLC","city":"Boise","state":"Idaho","zip":"83702","country":"United States","geoPoint":{"lat":43.6135,"lon":-116.20345}},{"facility":"Clinical Research Prime","city":"Idaho Falls","state":"Idaho","zip":"83404","country":"United States","geoPoint":{"lat":43.46658,"lon":-112.03414}},{"facility":"Clinical Research Prime Rexburg","city":"Rexburg","state":"Idaho","zip":"83440","country":"United States","geoPoint":{"lat":43.82602,"lon":-111.78969}},{"facility":"University of Chicago Medical Center","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"AMR Clinical","city":"El Dorado","state":"Kansas","zip":"67042","country":"United States","geoPoint":{"lat":37.81724,"lon":-96.86225}},{"facility":"AMR Clinical","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Kentucky Pediatric/ Adult Research","city":"Bardstown","state":"Kentucky","zip":"40004","country":"United States","geoPoint":{"lat":37.80923,"lon":-85.4669}},{"facility":"All Children Pediatrics","city":"Louisville","state":"Kentucky","zip":"40243","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"MD Medical Research","city":"Oxon Hill","state":"Maryland","zip":"20745","country":"United States","geoPoint":{"lat":38.80345,"lon":-76.9897}},{"facility":"White Oak Pediatrics","city":"Silver Spring","state":"Maryland","zip":"20904","country":"United States","geoPoint":{"lat":38.99067,"lon":-77.02609}},{"facility":"Sisu BHR","city":"Springfield","state":"Massachusetts","zip":"01103","country":"United States","geoPoint":{"lat":42.10148,"lon":-72.58981}},{"facility":"Michigan Center of Medical Research (MICHMER)","city":"Bingham Farms","state":"Michigan","zip":"48025","country":"United States","geoPoint":{"lat":42.51587,"lon":-83.27326}},{"facility":"Vida Clinical Studies, LLC","city":"Dearborn Heights","state":"Michigan","zip":"48127","country":"United States","geoPoint":{"lat":42.33698,"lon":-83.27326}},{"facility":"Great Lakes Research Institute","city":"Southfield","state":"Michigan","zip":"48075","country":"United States","geoPoint":{"lat":42.47337,"lon":-83.22187}},{"facility":"Clinical Research Institute","city":"Minneapolis","state":"Minnesota","zip":"55402","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"Velocity Clinical Research, Omaha","city":"Omaha","state":"Nebraska","zip":"68134","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Hassman Research Institute","city":"Marlton","state":"New Jersey","zip":"08053","country":"United States","geoPoint":{"lat":39.89122,"lon":-74.92183}},{"facility":"Rutgers University","city":"New Brunswick","state":"New Jersey","zip":"08901","country":"United States","geoPoint":{"lat":40.48622,"lon":-74.45182}},{"facility":"IMA Clinical Research Warren","city":"Warren Township","state":"New Jersey","zip":"07059","country":"United States","geoPoint":{"lat":40.60822,"lon":-74.51803}},{"facility":"Velocity Clinical Research, Binghamton","city":"Binghamton","state":"New York","zip":"13905","country":"United States","geoPoint":{"lat":42.09869,"lon":-75.91797}},{"facility":"Buffalo Clinical and Translational Research Center","city":"Buffalo","state":"New York","zip":"14203","country":"United States","geoPoint":{"lat":42.88645,"lon":-78.87837}},{"facility":"Advanced Specialty Care","city":"Commack","state":"New York","zip":"11725","country":"United States","geoPoint":{"lat":40.84288,"lon":-73.29289}},{"facility":"Smith Allergy and Asthma Specialists","city":"Cortland","state":"New York","zip":"13045","country":"United States","geoPoint":{"lat":42.60118,"lon":-76.18048}},{"facility":"Stony Brook Medicine Clinical Research Center","city":"East Setauket","state":"New York","zip":"11733","country":"United States","geoPoint":{"lat":40.94149,"lon":-73.10594}},{"facility":"Upstate Global Health Institute","city":"East Syracuse","state":"New York","zip":"13057","country":"United States","geoPoint":{"lat":43.06534,"lon":-76.07853}},{"facility":"Southampton Hospital","city":"Hampton Bays","state":"New York","zip":"11946","country":"United States","geoPoint":{"lat":40.86899,"lon":-72.51759}},{"facility":"Smith Allergy & Asthma Specialists","city":"Horseheads","state":"New York","zip":"14845","country":"United States","geoPoint":{"lat":42.16702,"lon":-76.82051}},{"facility":"NYU Langone Hospital - Long Island","city":"Mineola","state":"New York","zip":"11501","country":"United States","geoPoint":{"lat":40.74927,"lon":-73.64068}},{"facility":"DiGiovanna Institute for Medical Education & Research","city":"North Massapequa","state":"New York","zip":"11758","country":"United States","geoPoint":{"lat":40.70093,"lon":-73.46207}},{"facility":"Rochester Clinical Research, LLC","city":"Rochester","state":"New York","zip":"14609","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Stony Brook University","city":"Stony Brook","state":"New York","zip":"11794","country":"United States","geoPoint":{"lat":40.92565,"lon":-73.14094}},{"facility":"Prime Global Research","city":"The Bronx","state":"New York","zip":"10456","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"Advantage Clinical Trials","city":"The Bronx","state":"New York","zip":"10467","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"Velocity Clinical Research, Vestal","city":"Vestal","state":"New York","zip":"13850","country":"United States","geoPoint":{"lat":42.08507,"lon":-76.05381}},{"facility":"Centricity Research Columbus Ohio Multispecialty","city":"Columbus","state":"Ohio","zip":"43213","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Allegheny Health and Wellness Pavilion","city":"Erie","state":"Pennsylvania","zip":"16506","country":"United States","geoPoint":{"lat":42.12922,"lon":-80.08506}},{"facility":"Central Erie Primary Care","city":"Erie","state":"Pennsylvania","zip":"16508","country":"United States","geoPoint":{"lat":42.12922,"lon":-80.08506}},{"facility":"Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)","city":"Pittsburgh","state":"Pennsylvania","zip":"15236","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Northeast Clinical Trials Group","city":"Scranton","state":"Pennsylvania","zip":"18510","country":"United States","geoPoint":{"lat":41.40916,"lon":-75.6649}},{"facility":"Coastal Carolina Research Center","city":"North Charleston","state":"South Carolina","zip":"29405","country":"United States","geoPoint":{"lat":32.85462,"lon":-79.97481}},{"facility":"Benchmark Research","city":"Austin","state":"Texas","zip":"78705","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Benchmark Research","city":"Fort Worth","state":"Texas","zip":"76135","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"Texas Health Resources","city":"Fort Worth","state":"Texas","zip":"76135","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"C & R Research Services USA","city":"Houston","state":"Texas","zip":"77022","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"DM Clinical Research - Kool Kids Pediatrics","city":"Houston","state":"Texas","zip":"77065","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Research Your Health","city":"Plano","state":"Texas","zip":"75093","country":"United States","geoPoint":{"lat":33.01984,"lon":-96.69889}},{"facility":"Sun Research Institute","city":"San Antonio","state":"Texas","zip":"78215","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Velocity Clinical Research, Salt Lake City","city":"West Jordan","state":"Utah","zip":"84088","country":"United States","geoPoint":{"lat":40.60967,"lon":-111.9391}},{"facility":"Pediatric Research of Charlottesville, LLC","city":"Charlottesville","state":"Virginia","zip":"22902","country":"United States","geoPoint":{"lat":38.02931,"lon":-78.47668}},{"facility":"Clinical Research Partners, LLC","city":"Richmond","state":"Virginia","zip":"23226","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Frontier Clinical research","city":"Kingwood","state":"West Virginia","zip":"26537","country":"United States","geoPoint":{"lat":39.47176,"lon":-79.68339}},{"facility":"Preston Healthcare Services","city":"Kingwood","state":"West Virginia","zip":"26537","country":"United States","geoPoint":{"lat":39.47176,"lon":-79.68339}}]},"referencesModule":{"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://pmiform.com/clinical-trial-info-request?StudyID=C4601012"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests.","url":"https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"This study was conducted across 57 sites across the United States of America (USA).","recruitmentDetails":"A total of 3646 participants were enrolled, of which 3547 participants were randomized.","groups":[{"id":"FG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years were randomized to receive Lyme borreliosis 6-valent vaccine (VLA15 \\[PF-07307405\\]), 180 micrograms (ug), 0.5 milliliter (mL) intramuscular (IM) injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"FG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years were randomized to receive placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"FG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years were randomized to receive VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"FG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years were randomized to receive placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","comment":"Randomized participants as per the interventions assigned.","achievements":[{"groupId":"FG000","numSubjects":"1432"},{"groupId":"FG001","numSubjects":"475"},{"groupId":"FG002","numSubjects":"1221"},{"groupId":"FG003","numSubjects":"419"}]},{"type":"Vaccinated","comment":"Participants as per the interventions received.","achievements":[{"groupId":"FG000","numSubjects":"1429"},{"groupId":"FG001","numSubjects":"467"},{"groupId":"FG002","numSubjects":"1219"},{"groupId":"FG003","numSubjects":"418"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1209"},{"groupId":"FG001","numSubjects":"389"},{"groupId":"FG002","numSubjects":"997"},{"groupId":"FG003","numSubjects":"350"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"223"},{"groupId":"FG001","numSubjects":"86"},{"groupId":"FG002","numSubjects":"224"},{"groupId":"FG003","numSubjects":"69"}]}],"dropWithdraws":[{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"49"},{"groupId":"FG003","numSubjects":"16"}]},{"type":"No longer met eligibility criteria","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Withdrawal by parent or guardian","reasons":[{"groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"42"},{"groupId":"FG003","numSubjects":"11"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"96"},{"groupId":"FG001","numSubjects":"43"},{"groupId":"FG002","numSubjects":"106"},{"groupId":"FG003","numSubjects":"34"}]},{"type":"Medication error without associated adverse event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Randomized but not treated","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention.","groups":[{"id":"BG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"BG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"BG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"BG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1429"},{"groupId":"BG001","value":"467"},{"groupId":"BG002","value":"1219"},{"groupId":"BG003","value":"418"},{"groupId":"BG004","value":"3533"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.2","spread":"2.0"},{"groupId":"BG001","value":"8.2","spread":"2.0"},{"groupId":"BG002","value":"14.3","spread":"1.7"},{"groupId":"BG003","value":"14.3","spread":"1.7"},{"groupId":"BG004","value":"11","spread":"3.5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"653"},{"groupId":"BG001","value":"214"},{"groupId":"BG002","value":"596"},{"groupId":"BG003","value":"182"},{"groupId":"BG004","value":"1645"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"776"},{"groupId":"BG001","value":"253"},{"groupId":"BG002","value":"623"},{"groupId":"BG003","value":"236"},{"groupId":"BG004","value":"1888"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"240"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"268"},{"groupId":"BG003","value":"90"},{"groupId":"BG004","value":"673"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1181"},{"groupId":"BG001","value":"391"},{"groupId":"BG002","value":"944"},{"groupId":"BG003","value":"327"},{"groupId":"BG004","value":"2843"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"17"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"9"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"83"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"4"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"262"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"208"},{"groupId":"BG003","value":"72"},{"groupId":"BG004","value":"641"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"1081"},{"groupId":"BG001","value":"342"},{"groupId":"BG002","value":"947"},{"groupId":"BG003","value":"320"},{"groupId":"BG004","value":"2690"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"74"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"32"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 1","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in the electronic dairy (e-diary) or by investigators in case report form (CRF) after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on Center for Biologics Evaluation and Research (CBER) toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 through Day 7 after Study Vaccination 1 (Vaccination on Day 1, Month 0)","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1408"},{"groupId":"OG001","value":"457"},{"groupId":"OG002","value":"1206"},{"groupId":"OG003","value":"410"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","lowerLimit":"78.6","upperLimit":"82.8"},{"groupId":"OG001","value":"34.8","lowerLimit":"30.4","upperLimit":"39.4"},{"groupId":"OG002","value":"80.6","lowerLimit":"78.3","upperLimit":"82.8"},{"groupId":"OG003","value":"14.6","lowerLimit":"11.4","upperLimit":"18.4"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 2","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 through Day 7 after Study Vaccination 2 (Vaccination on Day 1, Month 2)","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1297"},{"groupId":"OG001","value":"431"},{"groupId":"OG002","value":"1112"},{"groupId":"OG003","value":"386"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.6","lowerLimit":"70.0","upperLimit":"75.0"},{"groupId":"OG001","value":"29.0","lowerLimit":"24.8","upperLimit":"33.5"},{"groupId":"OG002","value":"71.4","lowerLimit":"68.6","upperLimit":"74.0"},{"groupId":"OG003","value":"11.7","lowerLimit":"8.6","upperLimit":"15.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 3","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 through Day 7 after Study Vaccination 3 (Vaccination on Day 1, Month 6)","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1225"},{"groupId":"OG001","value":"391"},{"groupId":"OG002","value":"1054"},{"groupId":"OG003","value":"372"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.5","lowerLimit":"70.9","upperLimit":"75.9"},{"groupId":"OG001","value":"25.1","lowerLimit":"20.8","upperLimit":"29.7"},{"groupId":"OG002","value":"69.6","lowerLimit":"66.8","upperLimit":"72.4"},{"groupId":"OG003","value":"9.7","lowerLimit":"6.9","upperLimit":"13.1"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 through Day 7 after Study Vaccination 4 (Vaccination on Day 1, Month 18)","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1169"},{"groupId":"OG001","value":"384"},{"groupId":"OG002","value":"979"},{"groupId":"OG003","value":"349"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.0","lowerLimit":"74.5","upperLimit":"79.4"},{"groupId":"OG001","value":"24.7","lowerLimit":"20.5","upperLimit":"29.4"},{"groupId":"OG002","value":"71.6","lowerLimit":"68.7","upperLimit":"74.4"},{"groupId":"OG003","value":"11.7","lowerLimit":"8.6","upperLimit":"15.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days After Any Study Vaccination","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 through Day 7 after any study vaccination","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1428"},{"groupId":"OG001","value":"466"},{"groupId":"OG002","value":"1212"},{"groupId":"OG003","value":"415"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.3","lowerLimit":"86.5","upperLimit":"89.9"},{"groupId":"OG001","value":"56.0","lowerLimit":"51.4","upperLimit":"60.6"},{"groupId":"OG002","value":"90.0","lowerLimit":"88.2","upperLimit":"91.6"},{"groupId":"OG003","value":"31.6","lowerLimit":"27.1","upperLimit":"36.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 1","description":"Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 through Day 7 after Study Vaccination 1 (Vaccination on Day 1, Month 0)","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1406"},{"groupId":"OG001","value":"456"},{"groupId":"OG002","value":"1205"},{"groupId":"OG003","value":"410"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","lowerLimit":"53.3","upperLimit":"58.6"},{"groupId":"OG001","value":"41.0","lowerLimit":"36.5","upperLimit":"45.7"},{"groupId":"OG002","value":"62.2","lowerLimit":"59.4","upperLimit":"64.9"},{"groupId":"OG003","value":"48.8","lowerLimit":"43.8","upperLimit":"53.7"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 2","description":"Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 through Day 7 after Study Vaccination 2 (Vaccination on Day 1, Month 2)","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1296"},{"groupId":"OG001","value":"430"},{"groupId":"OG002","value":"1111"},{"groupId":"OG003","value":"386"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","lowerLimit":"45.3","upperLimit":"50.8"},{"groupId":"OG001","value":"30.2","lowerLimit":"25.9","upperLimit":"34.8"},{"groupId":"OG002","value":"55.3","lowerLimit":"52.3","upperLimit":"58.2"},{"groupId":"OG003","value":"31.6","lowerLimit":"27.0","upperLimit":"36.5"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 3","description":"Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 through Day 7 after Study Vaccination 3 (Vaccination on Day 1, Month 6)","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1224"},{"groupId":"OG001","value":"391"},{"groupId":"OG002","value":"1055"},{"groupId":"OG003","value":"371"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.5","lowerLimit":"44.6","upperLimit":"50.3"},{"groupId":"OG001","value":"27.6","lowerLimit":"23.2","upperLimit":"32.3"},{"groupId":"OG002","value":"51.6","lowerLimit":"48.5","upperLimit":"54.6"},{"groupId":"OG003","value":"26.1","lowerLimit":"21.7","upperLimit":"30.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)","description":"Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 through Day 7 after Study Vaccination 4 (Vaccination on Day 1, Month 18)","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1169"},{"groupId":"OG001","value":"384"},{"groupId":"OG002","value":"977"},{"groupId":"OG003","value":"349"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","lowerLimit":"50.6","upperLimit":"56.4"},{"groupId":"OG001","value":"28.1","lowerLimit":"23.7","upperLimit":"32.9"},{"groupId":"OG002","value":"54.8","lowerLimit":"51.6","upperLimit":"57.9"},{"groupId":"OG003","value":"28.4","lowerLimit":"23.7","upperLimit":"33.4"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days After Any Study Vaccination","description":"Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 through Day 7 after any study vaccination","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1427"},{"groupId":"OG001","value":"466"},{"groupId":"OG002","value":"1212"},{"groupId":"OG003","value":"415"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","lowerLimit":"75.5","upperLimit":"79.9"},{"groupId":"OG001","value":"60.1","lowerLimit":"55.5","upperLimit":"64.6"},{"groupId":"OG002","value":"82.1","lowerLimit":"79.8","upperLimit":"84.2"},{"groupId":"OG003","value":"63.1","lowerLimit":"58.3","upperLimit":"67.8"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With AEs Through 1 Month Following Study Vaccination 1","description":"An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 1 were included in this outcome measure. AEs included both serious AEs (SAEs) and non-SAEs.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 through 1 Month after Study Vaccination 1 (Vaccination on Day 1, Month 0)","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1426"},{"groupId":"OG001","value":"467"},{"groupId":"OG002","value":"1219"},{"groupId":"OG003","value":"418"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"2.6","upperLimit":"4.5"},{"groupId":"OG001","value":"3.0","lowerLimit":"1.6","upperLimit":"5.0"},{"groupId":"OG002","value":"3.1","lowerLimit":"2.2","upperLimit":"4.3"},{"groupId":"OG003","value":"4.5","lowerLimit":"2.8","upperLimit":"7.0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With AEs Through 1 Month Following Study Vaccination 2","description":"An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 2 were included in this outcome measure. AEs included both SAEs and non-SAEs.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 through 1 Month after Study Vaccination 2 (Vaccination on Day 1, Month 2)","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1371"},{"groupId":"OG001","value":"452"},{"groupId":"OG002","value":"1173"},{"groupId":"OG003","value":"406"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","lowerLimit":"1.7","upperLimit":"3.4"},{"groupId":"OG001","value":"2.2","lowerLimit":"1.1","upperLimit":"4.0"},{"groupId":"OG002","value":"1.5","lowerLimit":"0.9","upperLimit":"2.4"},{"groupId":"OG003","value":"2.2","lowerLimit":"1.0","upperLimit":"4.2"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With AEs Through 1 Month Following Study Vaccination 3","description":"An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 3 were included in this outcome measure. AEs included both SAEs and non-SAEs.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 through 1 Month after Study Vaccination 3 (Vaccination on Day 1, Month 6)","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1313"},{"groupId":"OG001","value":"428"},{"groupId":"OG002","value":"1126"},{"groupId":"OG003","value":"397"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","lowerLimit":"3.5","upperLimit":"5.8"},{"groupId":"OG001","value":"3.5","lowerLimit":"2.0","upperLimit":"5.7"},{"groupId":"OG002","value":"4.6","lowerLimit":"3.5","upperLimit":"6.0"},{"groupId":"OG003","value":"4.3","lowerLimit":"2.5","upperLimit":"6.8"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With AEs Through 1 Month Following Study Vaccination 4 (Booster Dose)","description":"An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 4 were included in this outcome measure. AEs included both SAEs and non-SAEs.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 through 1 Month after Study Vaccination 4 (Vaccination on Day 1, Month 18)","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1226"},{"groupId":"OG001","value":"396"},{"groupId":"OG002","value":"1019"},{"groupId":"OG003","value":"360"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","lowerLimit":"3.0","upperLimit":"5.3"},{"groupId":"OG001","value":"2.5","lowerLimit":"1.2","upperLimit":"4.6"},{"groupId":"OG002","value":"4.1","lowerLimit":"3.0","upperLimit":"5.5"},{"groupId":"OG003","value":"4.7","lowerLimit":"2.8","upperLimit":"7.5"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With AEs Through 1 Month Following Any Study Vaccination","description":"An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after any dose were included in this outcome measure.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 through 1 Month after any study vaccination","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1429"},{"groupId":"OG001","value":"467"},{"groupId":"OG002","value":"1219"},{"groupId":"OG003","value":"418"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","lowerLimit":"10.1","upperLimit":"13.5"},{"groupId":"OG001","value":"8.6","lowerLimit":"6.2","upperLimit":"11.5"},{"groupId":"OG002","value":"11.2","lowerLimit":"9.5","upperLimit":"13.1"},{"groupId":"OG003","value":"12.2","lowerLimit":"9.2","upperLimit":"15.7"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMCs) Throughout the Study","description":"An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. NDCMCs included conditions that were undiagnosed prior to study entry (diagnosed while in the study and confirmed not to be a preexisting condition) and that were not considered temporary conditions based upon the expected natural history of the condition. An NDCMC was not reported on AE CRF.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Throughout the study (from study vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months)","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1429"},{"groupId":"OG001","value":"467"},{"groupId":"OG002","value":"1219"},{"groupId":"OG003","value":"418"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","lowerLimit":"1.9","upperLimit":"3.7"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.9","upperLimit":"3.6"},{"groupId":"OG002","value":"2.1","lowerLimit":"1.4","upperLimit":"3.1"},{"groupId":"OG003","value":"3.3","lowerLimit":"1.8","upperLimit":"5.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study","description":"An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other important medical event.","populationDescription":"Safety population included all enrolled participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Throughout the study (from study vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months)","groups":[{"id":"OG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."},{"id":"OG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18."},{"id":"OG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1429"},{"groupId":"OG001","value":"467"},{"groupId":"OG002","value":"1219"},{"groupId":"OG003","value":"418"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.6","upperLimit":"1.7"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.2","upperLimit":"2.2"},{"groupId":"OG002","value":"2.2","lowerLimit":"1.5","upperLimit":"3.2"},{"groupId":"OG003","value":"2.4","lowerLimit":"1.2","upperLimit":"4.4"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"Local reactions and systemic events: Day 1 to Day 7 after each study vaccination; SAEs, All-cause mortality: Throughout the study (from study Vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months); Other AEs: From Day 1 through 1 Month after any study vaccination","description":"Same events may appear as both other AE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and other AE (non-SAE). Safety population included all enrolled participants who received at least 1 dose of the study intervention.","eventGroups":[{"id":"EG000","title":"VLA15: 5 to 11 Years","description":"Participants aged 5 to 11 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18.","deathsNumAffected":0,"deathsNumAtRisk":1429,"seriousNumAffected":15,"seriousNumAtRisk":1429,"otherNumAffected":1290,"otherNumAtRisk":1429},{"id":"EG001","title":"Placebo: 5 to 11 Years","description":"Participants aged 5 to 11 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18.","deathsNumAffected":0,"deathsNumAtRisk":467,"seriousNumAffected":4,"seriousNumAtRisk":467,"otherNumAffected":341,"otherNumAtRisk":467},{"id":"EG002","title":"VLA15: 12 to 17 Years","description":"Participants aged 12 to 17 years who received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18.","deathsNumAffected":0,"deathsNumAtRisk":1219,"seriousNumAffected":27,"seriousNumAtRisk":1219,"otherNumAffected":1121,"otherNumAtRisk":1219},{"id":"EG003","title":"Placebo: 12 to 17 Years","description":"Participants aged 12 to17 years who received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18.","deathsNumAffected":1,"deathsNumAtRisk":418,"seriousNumAffected":10,"seriousNumAtRisk":418,"otherNumAffected":295,"otherNumAtRisk":418},{"id":"EG004","title":"VLA15: Overall","description":"Participants aged 5 to 17 years received VLA15, 180 ug, 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a booster dose of VLA15 at Month 18.","deathsNumAffected":0,"deathsNumAtRisk":2648,"seriousNumAffected":42,"seriousNumAtRisk":2648,"otherNumAffected":2411,"otherNumAtRisk":2648},{"id":"EG005","title":"Placebo: Overall","description":"Participants aged 5 to 17 years received placebo (normal saline) 0.5 mL IM injection at Month 0, 2 and 6. Eligible participants received a placebo IM injection at Month 18.","deathsNumAffected":1,"deathsNumAtRisk":885,"seriousNumAffected":14,"seriousNumAtRisk":885,"otherNumAffected":636,"otherNumAtRisk":885}],"seriousEvents":[{"term":"Arnold-Chiari malformation","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Anal fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Crohn's disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1429},{"groupId":"EG001","numAffected":1,"numAtRisk":467},{"groupId":"EG002","numAffected":2,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":3,"numAtRisk":2648},{"groupId":"EG005","numAffected":1,"numAtRisk":885}]},{"term":"Appendicitis perforated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":2,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":2,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Cellulitis orbital","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Food allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Influenza myocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Mastoiditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Mycoplasma infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":1,"numAtRisk":418},{"groupId":"EG004","numAffected":0,"numAtRisk":2648},{"groupId":"EG005","numAffected":1,"numAtRisk":885}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":1,"numAtRisk":418},{"groupId":"EG004","numAffected":0,"numAtRisk":2648},{"groupId":"EG005","numAffected":1,"numAtRisk":885}]},{"term":"Periorbital abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":1,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":0,"numAtRisk":2648},{"groupId":"EG005","numAffected":1,"numAtRisk":885}]},{"term":"Periorbital cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":1,"numAtRisk":418},{"groupId":"EG004","numAffected":0,"numAtRisk":2648},{"groupId":"EG005","numAffected":1,"numAtRisk":885}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":2,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Respiratory tract infection viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Subperiosteal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":1,"numAtRisk":418},{"groupId":"EG004","numAffected":0,"numAtRisk":2648},{"groupId":"EG005","numAffected":1,"numAtRisk":885}]},{"term":"Forearm fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Tibia fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":1,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":1,"numAtRisk":885}]},{"term":"Vulvovaginal injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":2,"numAtRisk":418},{"groupId":"EG004","numAffected":0,"numAtRisk":2648},{"groupId":"EG005","numAffected":2,"numAtRisk":885}]},{"term":"Type 1 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":1,"numAtRisk":418},{"groupId":"EG004","numAffected":2,"numAtRisk":2648},{"groupId":"EG005","numAffected":1,"numAtRisk":885}]},{"term":"Chronic recurrent multifocal osteomyelitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Hodgkin's disease nodular sclerosis stage IV","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Central nervous system lesion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":1,"numAtRisk":418},{"groupId":"EG004","numAffected":0,"numAtRisk":2648},{"groupId":"EG005","numAffected":1,"numAtRisk":885}]},{"term":"Tethered cord syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":2,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":3,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Disruptive mood dysregulation disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Drug abuse","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":1,"numAtRisk":418},{"groupId":"EG004","numAffected":0,"numAtRisk":2648},{"groupId":"EG005","numAffected":1,"numAtRisk":885}]},{"term":"Oppositional defiant disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":1,"numAtRisk":467},{"groupId":"EG002","numAffected":3,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":3,"numAtRisk":2648},{"groupId":"EG005","numAffected":1,"numAtRisk":885}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":2,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":2,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1429},{"groupId":"EG001","numAffected":1,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":1,"numAtRisk":885}]},{"term":"Asthmatic crisis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":1,"numAtRisk":418},{"groupId":"EG004","numAffected":0,"numAtRisk":2648},{"groupId":"EG005","numAffected":1,"numAtRisk":885}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Pharyngeal oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Tracheal stenosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Angioedema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":1,"numAtRisk":418},{"groupId":"EG004","numAffected":0,"numAtRisk":2648},{"groupId":"EG005","numAffected":1,"numAtRisk":885}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":0,"numAtRisk":1219},{"groupId":"EG003","numAffected":1,"numAtRisk":418},{"groupId":"EG004","numAffected":0,"numAtRisk":2648},{"groupId":"EG005","numAffected":1,"numAtRisk":885}]},{"term":"Substance-induced psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":1,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":1,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]}],"otherEvents":[{"term":"Fatigue (FATIGUE)","organSystem":"General disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":875,"numAtRisk":1429},{"groupId":"EG001","numAffected":219,"numAtRisk":467},{"groupId":"EG002","numAffected":769,"numAtRisk":1219},{"groupId":"EG003","numAffected":193,"numAtRisk":418},{"groupId":"EG004","numAffected":1644,"numAtRisk":2648},{"groupId":"EG005","numAffected":412,"numAtRisk":885}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":12,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":32,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":40,"numAtRisk":1429},{"groupId":"EG001","numAffected":4,"numAtRisk":467},{"groupId":"EG002","numAffected":29,"numAtRisk":1219},{"groupId":"EG003","numAffected":4,"numAtRisk":418},{"groupId":"EG004","numAffected":69,"numAtRisk":2648},{"groupId":"EG005","numAffected":8,"numAtRisk":885}]},{"term":"Injection site pain (PAIN AT INJECTION SITE)","organSystem":"General disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1245,"numAtRisk":1429},{"groupId":"EG001","numAffected":250,"numAtRisk":467},{"groupId":"EG002","numAffected":1084,"numAtRisk":1219},{"groupId":"EG003","numAffected":130,"numAtRisk":418},{"groupId":"EG004","numAffected":2329,"numAtRisk":2648},{"groupId":"EG005","numAffected":380,"numAtRisk":885}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":1429},{"groupId":"EG001","numAffected":0,"numAtRisk":467},{"groupId":"EG002","numAffected":7,"numAtRisk":1219},{"groupId":"EG003","numAffected":0,"numAtRisk":418},{"groupId":"EG004","numAffected":27,"numAtRisk":2648},{"groupId":"EG005","numAffected":0,"numAtRisk":885}]},{"term":"Pyrexia (FEVER)","organSystem":"General disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":193,"numAtRisk":1429},{"groupId":"EG001","numAffected":29,"numAtRisk":467},{"groupId":"EG002","numAffected":89,"numAtRisk":1219},{"groupId":"EG003","numAffected":19,"numAtRisk":418},{"groupId":"EG004","numAffected":282,"numAtRisk":2648},{"groupId":"EG005","numAffected":48,"numAtRisk":885}]},{"term":"Swelling (SWELLING)","organSystem":"General disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":752,"numAtRisk":1429},{"groupId":"EG001","numAffected":45,"numAtRisk":467},{"groupId":"EG002","numAffected":277,"numAtRisk":1219},{"groupId":"EG003","numAffected":7,"numAtRisk":418},{"groupId":"EG004","numAffected":1029,"numAtRisk":2648},{"groupId":"EG005","numAffected":52,"numAtRisk":885}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":1429},{"groupId":"EG001","numAffected":2,"numAtRisk":467},{"groupId":"EG002","numAffected":10,"numAtRisk":1219},{"groupId":"EG003","numAffected":9,"numAtRisk":418},{"groupId":"EG004","numAffected":28,"numAtRisk":2648},{"groupId":"EG005","numAffected":11,"numAtRisk":885}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":1429},{"groupId":"EG001","numAffected":6,"numAtRisk":467},{"groupId":"EG002","numAffected":5,"numAtRisk":1219},{"groupId":"EG003","numAffected":4,"numAtRisk":418},{"groupId":"EG004","numAffected":17,"numAtRisk":2648},{"groupId":"EG005","numAffected":10,"numAtRisk":885}]},{"term":"Pharyngitis streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":47,"numAtRisk":1429},{"groupId":"EG001","numAffected":14,"numAtRisk":467},{"groupId":"EG002","numAffected":12,"numAtRisk":1219},{"groupId":"EG003","numAffected":5,"numAtRisk":418},{"groupId":"EG004","numAffected":59,"numAtRisk":2648},{"groupId":"EG005","numAffected":19,"numAtRisk":885}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":1429},{"groupId":"EG001","numAffected":13,"numAtRisk":467},{"groupId":"EG002","numAffected":24,"numAtRisk":1219},{"groupId":"EG003","numAffected":16,"numAtRisk":418},{"groupId":"EG004","numAffected":55,"numAtRisk":2648},{"groupId":"EG005","numAffected":29,"numAtRisk":885}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1429},{"groupId":"EG001","numAffected":5,"numAtRisk":467},{"groupId":"EG002","numAffected":5,"numAtRisk":1219},{"groupId":"EG003","numAffected":3,"numAtRisk":418},{"groupId":"EG004","numAffected":7,"numAtRisk":2648},{"groupId":"EG005","numAffected":8,"numAtRisk":885}]},{"term":"Arthralgia (JOINT PAIN)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":375,"numAtRisk":1429},{"groupId":"EG001","numAffected":64,"numAtRisk":467},{"groupId":"EG002","numAffected":353,"numAtRisk":1219},{"groupId":"EG003","numAffected":65,"numAtRisk":418},{"groupId":"EG004","numAffected":728,"numAtRisk":2648},{"groupId":"EG005","numAffected":129,"numAtRisk":885}]},{"term":"Myalgia (MUSCLE PAIN)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":717,"numAtRisk":1429},{"groupId":"EG001","numAffected":112,"numAtRisk":467},{"groupId":"EG002","numAffected":637,"numAtRisk":1219},{"groupId":"EG003","numAffected":110,"numAtRisk":418},{"groupId":"EG004","numAffected":1354,"numAtRisk":2648},{"groupId":"EG005","numAffected":222,"numAtRisk":885}]},{"term":"Headache (HEADACHE)","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":750,"numAtRisk":1429},{"groupId":"EG001","numAffected":192,"numAtRisk":467},{"groupId":"EG002","numAffected":734,"numAtRisk":1219},{"groupId":"EG003","numAffected":180,"numAtRisk":418},{"groupId":"EG004","numAffected":1484,"numAtRisk":2648},{"groupId":"EG005","numAffected":372,"numAtRisk":885}]},{"term":"Attention deficit hyperactivity disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":1429},{"groupId":"EG001","numAffected":8,"numAtRisk":467},{"groupId":"EG002","numAffected":7,"numAtRisk":1219},{"groupId":"EG003","numAffected":5,"numAtRisk":418},{"groupId":"EG004","numAffected":34,"numAtRisk":2648},{"groupId":"EG005","numAffected":13,"numAtRisk":885}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1429},{"groupId":"EG001","numAffected":1,"numAtRisk":467},{"groupId":"EG002","numAffected":9,"numAtRisk":1219},{"groupId":"EG003","numAffected":7,"numAtRisk":418},{"groupId":"EG004","numAffected":11,"numAtRisk":2648},{"groupId":"EG005","numAffected":8,"numAtRisk":885}]},{"term":"Erythema (REDNESS)","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRAv28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":891,"numAtRisk":1429},{"groupId":"EG001","numAffected":76,"numAtRisk":467},{"groupId":"EG002","numAffected":305,"numAtRisk":1219},{"groupId":"EG003","numAffected":12,"numAtRisk":418},{"groupId":"EG004","numAffected":1196,"numAtRisk":2648},{"groupId":"EG005","numAffected":88,"numAtRisk":885}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2022-07-25","uploadDate":"2026-04-13T22:45","filename":"Prot_000.pdf","size":11201277},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2025-08-01","uploadDate":"2026-04-13T22:45","filename":"SAP_001.pdf","size":337262}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D008193","term":"Lyme Disease"},{"id":"D001899","term":"Borrelia Infections"},{"id":"D000079426","term":"Vector Borne Diseases"}],"ancestors":[{"id":"D016905","term":"Gram-Negative Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"},{"id":"D013145","term":"Spirochaetales Infections"},{"id":"D017282","term":"Tick-Borne Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077330","term":"Saline Solution"}],"ancestors":[{"id":"D000077324","term":"Crystalloid Solutions"},{"id":"D007552","term":"Isotonic Solutions"},{"id":"D012996","term":"Solutions"},{"id":"D004364","term":"Pharmaceutical Preparations"}]}},"hasResults":true}